Article
Genentech And AbbVie: Venclexta Combo Fails To Extend Survival In Phase III Trial For High-Risk MDS
Neutral
0.0
−100 Bearish
0
+100 Bullish
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), and AbbVie announced that The Phase III VERONA study, which evaluated Venclexta or venetoclax in combination with azacitidine for patients with previously untreated higher-risk myelodysplastic syndromes, did not meet its
Actions
Pulse AI
Pulse analysis not available yet. Click "Get Pulse" above.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
Article Info
Source
NASDAQ Markets
Published
Jun 17, 2025 · 1:40 am
Article ID
25798602212985155579
Original URL
Open source
Sentiment Signal
Neutral
0.0
−100Neutral+100
More Like This